Genetic testing company 23andMe (ME) is being sued by 27 states and Washington, DC to oppose the sale of DNA data from its customers without their direct consent, The New York Times’ Rylee Kirk reports. The suit, filed on Monday in U.S. Bankruptcy Court in the Eastern District of Missouri, argues that 23andMe needs to have permission from each and every customer before their data is potentially sold and that the information for sale “comprises an unprecedented compilation of highly sensitive and immutable personal data of consumers.” 23andMe filed for bankruptcy in March, and is poised to be acquired by Regeneron Pharmaceuticals (REGN) for $256M, the lawsuit notes.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on REGN:
- Regeneron Hold Rating: Eylea Developments and Future Pipeline Focus
- VOO ETF News, 6/9/2025
- JPMorgan cuts Regeneron target, says selloff ‘very much overdone’
- Regeneron Buy Rating: Undervalued Stock with Strong Fundamentals and Growth Catalysts
- Regeneron, Sanofi presents results from DISCOVER Phase 4 trial of Dupixent